LOXL2 and neoplasm: Taken together, TCGA and IHC studies of human squamous cell tongue cancer support that LOXL2 is expressed at high levels in poorly differentiated and well-differentiated oral cancer by tumor cells and mesenchymal cells, and further support the notion that LOXL2 likely contributes to the etiology of metastatic disease.